Intervention not reported
MD‐TRIPLE (Direct evidence; 3 RCTs; 3184 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
1 finding from 1 review
Intervention not reported
HD‐TRIPLE (Direct evidence; 2 RCTs; 2037 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
1 finding from 1 review
Intervention not reported
MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
HD Triple vs. MD Triple · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
HD‐TRIPLE (Direct evidence; 3 RCTs; 3470 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
1 finding from 1 review
Intervention not reported
MD Triple · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life (Asthma Quality of Life Questionnaire, with 32 items, 0 to 7 points per item) · People with asthma (mostly mild or moderate)
1 finding from 1 review
Intervention not reported
Asthma symptoms (different severity scores; change from baseline) · People with asthma (mostly mild or moderate)
1 finding from 1 review
Intervention not reported
Asthma control (weekly number of attacks) · People with asthma (mostly mild or moderate)
1 finding from 1 review
Intervention not reported
Forced expiratory volume in one second (change from baseline FEV1 (L)) · People with asthma (mostly mild or moderate)
1 finding from 1 review
Intervention not reported
Reduced asthma medication usage · People with asthma (mostly mild or moderate)
The intervention may leads to higher reduced asthma medication usage (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events · People with asthma (mostly mild or moderate)
1 finding from 1 review
Change in baseline trough FEV1 · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
1 finding from 1 review
All‐cause serious adverse events · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium leads to lower all‐cause serious adverse events compared with ipratropium (high certainty).
1 finding from 1 review
Hospital admissions · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium probably leads to lower hospital admissions (all‐cause) compared with ipratropium (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium showed no clear difference in mortality (all‐cause) compared with ipratropium (moderate certainty).
1 finding from 1 review
Quality of life ( · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
1 finding from 1 review
Exacerbations · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium leads to lower patients with one or more exacerbations compared with ipratropium (high certainty).
1 finding from 1 review
Treatment withdrawal · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium leads to lower withdrawals compared with ipratropium (high certainty).
1 finding from 1 review
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · adults with asthma
1 finding from 1 review